Stay updated on Flotetuzumab in PIF/ER AML Clinical Trial
Sign up to get notified when there's something new on the Flotetuzumab in PIF/ER AML Clinical Trial page.

Latest updates to the Flotetuzumab in PIF/ER AML Clinical Trial page
- Check3 days agoChange DetectedA government-funding notice was added about the NIH Clinical Center's status, and the page revision version updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check10 days agoChange DetectedShow glossary is now available; Last Update Submitted that Met QC Criteria, No FEAR Act Data, and Revision: v3.4.0 are added, while Last Update Submitted that met QC Criteria, No FEAR Act data, and Revision: v3.3.4 were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedPage revision updated from v3.3.3 to v3.3.4.SummaryDifference0.0%

- Check46 days agoChange DetectedIntroduced a consolidated Locations section listing states and District of Columbia (California, District of Columbia, Florida, Georgia, Illinois, Maryland, Michigan, Missouri, New York, North Carolina, Ohio, Oregon, Tennessee, Texas, Washington, Wisconsin) and removed the separate per-state location pages.SummaryDifference1%

- Check74 days agoChange DetectedEditorial changes were made to the Publications section: a new note clarifies that PubMed-listed publications are automatically filled, and the page’s revision tag was updated to v3.3.2; a corresponding older note about PubMed-derived publications was removed and replaced (Revision: v3.2.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check81 days agoChange DetectedA government funding status notice banner was removed from the page, and this does not affect the study's details, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Flotetuzumab in PIF/ER AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Flotetuzumab in PIF/ER AML Clinical Trial page.